Literature DB >> 35586421

Synthesis and Biological Characterization of a Series of 2-Sulfonamidebenzamides as Allosteric Modulators of MrgX1.

Swagat Sharma1, Qi Peng2, Anish K Vadukoot1, Christopher D Aretz1, Aaron A Jensen1, Alexander I Wallick1, Xinzhong Dong2,3, Corey R Hopkins1.   

Abstract

The present study describes our continued efforts in the discovery and characterization of a series of 2-sulfonamidebenzamides as allosteric modulators of MrgX1. MrgX1 has been shown to be an attractive target as a nonopioid receptor for the potential treatment of chronic pain. Working from our original compound, ML382, and utilizing iterative medicinal chemistry, we have identified key halogen substituents that improve MrgX1 potency by ∼8-fold. In addition, we have evaluated the compounds in Tier 1 drug metabolism and pharmacokinetics assays and have identified key compounds that impart improved potency and microsomal stability.
© 2022 American Chemical Society.

Entities:  

Year:  2022        PMID: 35586421      PMCID: PMC9109276          DOI: 10.1021/acsmedchemlett.2c00100

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.632


  13 in total

1.  Advancing a national agenda to eliminate disparities in pain care: directions for health policy, education, practice, and research.

Authors:  Salimah H Meghani; Rosemary C Polomano; Raymond C Tait; April H Vallerand; Karen O Anderson; Rollin M Gallagher
Journal:  Pain Med       Date:  2011-12-05       Impact factor: 3.750

Review 2.  The application of cassette dosing for pharmacokinetic screening in small-molecule cancer drug discovery.

Authors:  Nicola F Smith; Florence I Raynaud; Paul Workman
Journal:  Mol Cancer Ther       Date:  2007-02       Impact factor: 6.261

3.  Strategic use of plasma and microsome binding to exploit in vitro clearance in early drug discovery.

Authors:  George Chang; Stefanus J Steyn; John P Umland; Dennis O Scott
Journal:  ACS Med Chem Lett       Date:  2010-02-03       Impact factor: 4.345

4.  Synthesis and SAR of a novel metabotropic glutamate receptor 4 (mGlu4) antagonist: unexpected 'molecular switch' from a closely related mGlu4 positive allosteric modulator.

Authors:  Thomas Utley; Dustin Haddenham; James M Salovich; Rocio Zamorano; Paige N Vinson; Craig W Lindsley; Corey R Hopkins; Colleen M Niswender
Journal:  Bioorg Med Chem Lett       Date:  2011-10-08       Impact factor: 2.823

5.  Targeting human Mas-related G protein-coupled receptor X1 to inhibit persistent pain.

Authors:  Zhe Li; Pang-Yen Tseng; Vinod Tiwari; Qian Xu; Shao-Qiu He; Yan Wang; Qin Zheng; Liang Han; Zhiping Wu; Anna L Blobaum; Yiyuan Cui; Vineeta Tiwari; Shuohao Sun; Yingying Cheng; Julie H Y Huang-Lionnet; Yixun Geng; Bo Xiao; Junmin Peng; Corey Hopkins; Srinivasa N Raja; Yun Guan; Xinzhong Dong
Journal:  Proc Natl Acad Sci U S A       Date:  2017-02-21       Impact factor: 11.205

6.  Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer.

Authors:  Gui-Dong Zhu; Jianchun Gong; Viraj B Gandhi; Xuesong Liu; Yan Shi; Eric F Johnson; Cherrie K Donawho; Paul A Ellis; Jennifer J Bouska; Donald J Osterling; Amanda M Olson; Chang Park; Yan Luo; Alexander Shoemaker; Vincent L Giranda; Thomas D Penning
Journal:  Bioorg Med Chem       Date:  2012-06-19       Impact factor: 3.641

7.  Nociceptor sensitization in pain pathogenesis.

Authors:  Michael S Gold; Gerald F Gebhart
Journal:  Nat Med       Date:  2010-10-14       Impact factor: 53.440

8.  The discovery of VU0486846: steep SAR from a series of M1 PAMs based on a novel benzomorpholine core.

Authors:  Jeanette L Bertron; Hyekyung P Cho; Pedro M Garcia-Barrantes; Joseph D Panarese; James M Salovich; Kellie D Nance; Darren W Engers; Jerri M Rook; Anna L Blobaum; Colleen M Niswender; Shaun R Stauffer; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2018-05-05       Impact factor: 2.823

9.  Discovery and characterization of 2-(cyclopropanesulfonamido)-N-(2-ethoxyphenyl)benzamide, ML382: a potent and selective positive allosteric modulator of MrgX1.

Authors:  Wandong Wen; Yan Wang; Zhe Li; Pang-Yen Tseng; Owen B McManus; Meng Wu; Min Li; Craig W Lindsley; Xinzhong Dong; Corey R Hopkins
Journal:  ChemMedChem       Date:  2014-09-10       Impact factor: 3.466

10.  Automated design of ligands to polypharmacological profiles.

Authors:  Jérémy Besnard; Gian Filippo Ruda; Vincent Setola; Keren Abecassis; Ramona M Rodriguiz; Xi-Ping Huang; Suzanne Norval; Maria F Sassano; Antony I Shin; Lauren A Webster; Frederick R C Simeons; Laste Stojanovski; Annik Prat; Nabil G Seidah; Daniel B Constam; G Richard Bickerton; Kevin D Read; William C Wetsel; Ian H Gilbert; Bryan L Roth; Andrew L Hopkins
Journal:  Nature       Date:  2012-12-13       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.